Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
about
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-AmyloidDose and plasma concentration of galantamine in Alzheimer's disease - clinical application.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid loadCerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Benefits and risks of add-on therapies for Alzheimer's disease.Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease.Two galantamine titration regimens in patients switched from donepezil.Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease.A Highly Sensitive Gold-Nanoparticle-Based Assay for Acetylcholinesterase in Cerebrospinal Fluid of Transgenic Mice with Alzheimer's Disease
P2860
Q33596451-7E728D66-C08E-4112-AA63-6598980FCF5CQ35006354-EB758929-3826-428C-BC4A-C0A17800C641Q35060833-1CFBA110-FA82-4615-B538-9128A69A4F46Q35210180-23CA46B9-BB80-4165-A71B-B949842B938AQ36632702-F379AEFF-D186-4FF5-8AC9-63A2D88862D5Q37070395-5820C877-5DE6-4820-A2A9-456B23E5CA1BQ37158584-C5BE61B5-BBFD-4246-8554-71A25B9D27C0Q38289739-0448CD29-CF01-4D88-A6A7-0474D32789EEQ38620338-4C42CFAD-2637-4C2A-BBF4-96B23D8DD847Q47956147-27796605-B8CB-4F24-B409-07370D4CE04CQ50783671-4C1F6D7A-A98C-442C-9089-B196898B9BC3Q53337462-BBC1221D-D527-435F-AE3D-457AE387B36FQ57238765-FF5C3DED-D3A9-493B-B663-8A45433CC2BE
P2860
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Changes in CSF acetyl- and but ...... bitors in Alzheimer's disease.
@en
Changes in CSF acetyl- and but ...... bitors in Alzheimer's disease.
@nl
type
label
Changes in CSF acetyl- and but ...... bitors in Alzheimer's disease.
@en
Changes in CSF acetyl- and but ...... bitors in Alzheimer's disease.
@nl
prefLabel
Changes in CSF acetyl- and but ...... bitors in Alzheimer's disease.
@en
Changes in CSF acetyl- and but ...... bitors in Alzheimer's disease.
@nl
P2093
P2860
P50
P1476
Changes in CSF acetyl- and but ...... bitors in Alzheimer's disease.
@en
P2093
A K Wallin
D Chiasserini
L Parnetti
N Andreasen
U Andreasson
V N Talesa
P2860
P304
P356
10.1111/J.1600-0404.2010.01435.X
P407
P577
2010-09-29T00:00:00Z